Organogenesis Holdings Inc.

NasdaqCM:ORGO Stock Report

Market Cap: US$331.4m

Organogenesis Holdings Management

Management criteria checks 3/4

Organogenesis Holdings' CEO is Gary Gillheeney, appointed in Jan 2014, has a tenure of 10.42 years. total yearly compensation is $6.24M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth $2.10M. The average tenure of the management team and the board of directors is 6.8 years and 3.6 years respectively.

Key information

Gary Gillheeney

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage14.6%
CEO tenure10.4yrs
CEO ownership0.6%
Management average tenure6.8yrs
Board average tenure3.6yrs

Recent management updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Jun 10
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis Holdings: What Now

May 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Nov 30
Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

CEO Compensation Analysis

How has Gary Gillheeney's remuneration changed compared to Organogenesis Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

US$6m

Dec 31 2023US$6mUS$909k

US$5m

Sep 30 2023n/an/a

US$13m

Jun 30 2023n/an/a

US$10m

Mar 31 2023n/an/a

US$13m

Dec 31 2022US$6mUS$883k

US$16m

Sep 30 2022n/an/a

US$59m

Jun 30 2022n/an/a

US$71m

Mar 31 2022n/an/a

US$83m

Dec 31 2021US$4mUS$835k

US$94m

Sep 30 2021n/an/a

US$62m

Jun 30 2021n/an/a

US$69m

Mar 31 2021n/an/a

US$43m

Dec 31 2020US$3mUS$823k

US$17m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$819k

-US$39m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$58m

Dec 31 2018US$3mUS$798k

-US$65m

Sep 30 2018n/an/a

-US$60m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$32m

Dec 31 2017US$1mUS$780k

-US$9m

Compensation vs Market: Gary's total compensation ($USD6.24M) is above average for companies of similar size in the US market ($USD2.47M).

Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.


CEO

Gary Gillheeney (69 yo)

10.4yrs

Tenure

US$6,244,671

Compensation

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...


Leadership Team

NamePositionTenureCompensationOwnership
Gary Gillheeney
President10.4yrsUS$6.24m0.63%
$ 2.1m
David Francisco
Chief Financial Officer3.3yrsUS$1.63m0.048%
$ 159.6k
Patrick Bilbo
Chief Operating Officer6.8yrsUS$2.16m0.26%
$ 867.7k
Lori Freedman
Chief Administrative & Legal Officer7.4yrsUS$1.99m0.063%
$ 209.8k
Brian Grow
Chief Commercial Officer6.8yrsUS$1.92m0.078%
$ 259.5k
William Kolb
Secretaryno datano datano data
Robert Cavorsi
Vice President of Strategy3.4yrsno datano data

6.8yrs

Average Tenure

57.5yo

Average Age

Experienced Management: ORGO's management team is seasoned and experienced (6.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gary Gillheeney
President5.5yrsUS$6.24m0.63%
$ 2.1m
Glenn Nussdorf
Director21.4yrsno data11.29%
$ 37.4m
Alan Ades
Director21.4yrsno data11.5%
$ 38.1m
Arthur Leibowitz
Lead Independent Director5.5yrsUS$291.46k0.10%
$ 341.5k
Robert Ades
Director3.6yrsno datano data
Jon Giacomin
Independent Director3.1yrsUS$265.00k0.068%
$ 224.6k
Michele Korfin
Independent Director2.1yrsUS$226.98k0.068%
$ 224.1k
Prathyusha Duraibabu
Independent Director2.6yrsUS$240.00k0.071%
$ 234.6k
David Erani
Director3.6yrsno datano data
Michael Driscoll
Independent Director2.3yrsUS$230.52kno data
Gilberto Quintero
Independent Director2.1yrsUS$226.98k0.068%
$ 224.1k

3.6yrs

Average Tenure

59yo

Average Age

Experienced Board: ORGO's board of directors are considered experienced (3.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.